Over 5,000 patients with HCV will be treated with PEGASYS plus COPEGUS in this large international observational study. Patients will be monitored during treatment and for a further 24 weeks after ...

The FDA has approved revisions to the safety labeling for nevirapine tablets and oral suspension (Viramune), ribavirin tablets (Copegus), and atovaquone plus proguanil HCl and pediatric tablets ...

The Business Research Company's Pegasys Copegus Global market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

The Pegasys Copegus combination pack is a well-established treatment for chronic hepatitis C patients. It combines peginterferon alfa-2a (Pegasys), which enhances immune response, and ribavirin ...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved combination therapy with Pegasys (peginterferon alfa-2a), a pegylated interferon, and Copegus (ribavirin) for the ...

Roche today announced final results from the REPEAT study, which demonstrate that treatment with once-weekly PEGASYS (R) (peginterferon alfa-2a (40KD)) and daily COPEGUS (R) (ribavirin) can ...

The FDA has approved new indications for candesartan cilexitil (Atacand) and peginterferon alfa-2a [40 KD] (Pegasys) plus ribavirin (Copegus) combination therapy, and a urine screening test for ...

Ribapharm has sued. "There are always discussions going on between us and Ribapharm," says Roche's Gemayel, "but we don't believe there is anything that will prevent Copegus from getting approved." ...

Roche and InterMune, Inc. have announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, R7227/ ITMN 191, in combination with ...